Healthcare provider profile · identity verified

Yiukei Poon, D.O.

Internal Medicine · OAKLAND, CA · NPI 1285946277

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1012	323
Amlodipine Besylate	Amlodipine Besylate	573	187
Losartan Potassium	Losartan Potassium	453	152
Lisinopril	Lisinopril	246	78
Atenolol	Atenolol	197	55
Metformin Hcl Er	Metformin Hcl	195	65
Tamsulosin Hcl	Tamsulosin Hcl	170	62
Fluticasone Propionate	Fluticasone Propionate	167	74
Metformin Hcl	Metformin Hcl	158	51
Famotidine	Famotidine	149	80
Metoprolol Tartrate	Metoprolol Tartrate	147	45
Alendronate Sodium	Alendronate Sodium	141	52
Simvastatin	Simvastatin	137	42
Levothyroxine Sodium	Levothyroxine Sodium	131	39
Gabapentin	Gabapentin	109	53
Omeprazole	Omeprazole	105	48
Allopurinol	Allopurinol	102	36
Triamcinolone Acetonide	Triamcinolone Acetonide	101	64
Finasteride	Finasteride	98	32
Pantoprazole Sodium	Pantoprazole Sodium	91	42
Glipizide	Glipizide	82	27
Jardiance	Empagliflozin	82	31
Albuterol Sulfate Hfa	Albuterol Sulfate	72	38
Metoprolol Succinate	Metoprolol Succinate	71	23
Terazosin Hcl	Terazosin Hcl	65	21
Lovastatin	Lovastatin	64	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	61	20
Colchicine	Colchicine	58	28
Trazodone Hcl	Trazodone Hcl	56	30
Amoxicillin	Amoxicillin	55	20
Fluocinonide	Fluocinonide	55	29
Hydrochlorothiazide	Hydrochlorothiazide	53	17
Wixela Inhub	Fluticasone Propion/Salmeterol	50	11
Furosemide	Furosemide	47	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	12
Ibuprofen	Ibuprofen	41	19
Mirtazapine	Mirtazapine	41	29
Hydrocortisone	Hydrocortisone	38	28
Clopidogrel	Clopidogrel Bisulfate	36	11
Meloxicam	Meloxicam	36	25
Tizanidine Hcl	Tizanidine Hcl	36	31
Montelukast Sodium	Montelukast Sodium	35	15
Alvesco	Ciclesonide	34	27
Clobetasol Propionate	Clobetasol Propionate	32	21
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	31	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	29	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	28	28
Betamethasone Valerate	Betamethasone Valerate	28	15
Glipizide Er	Glipizide	27	11
Propranolol Hcl	Propranolol Hcl	27	16
Naproxen	Naproxen	25	11
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Carvedilol	Carvedilol	23	suppressed
Lactulose	Lactulose	23	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	23	11
Tacrolimus	Tacrolimus	23	17
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	22	12
Prednisone	Prednisone	22	18
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Lorazepam	Lorazepam	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Cefadroxil	Cefadroxil	20	20
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	20	suppressed
Lidocaine	Lidocaine	20	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Azithromycin	Azithromycin	18	14
Digoxin	Digoxin	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Metronidazole	Metronidazole	15	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	15	suppressed
Entecavir	Entecavir	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Mupirocin	Mupirocin	14	12
Nifedipine Er	Nifedipine	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Trospium Chloride	Trospium Chloride	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Humulin N	Insulin Nph Human Isophane	12	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error